Atezolizumab

Tiragolumab and atezolizumab in metastatic esophageal cancer 0:39
Tiragolumab and atezolizumab in metastatic esophageal cancer
Zev Wainberg • 30 Jun 2021
Improving outcomes in HCC with immunotherapy 1:56
Improving outcomes in HCC with immunotherapy
Arndt Vogel • 11 Jun 2021
Disease-free survival in IMpower010 trial: adjuvant atezolizumab in NSCLC 2:44
Disease-free survival in IMpower010 trial: adjuvant atezolizumab in NSCLC
Sanjay Popat • 11 Jun 2021
Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer 3:02
Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer
Heather A. Wakelee • 9 Jun 2021
FORT-2: rogaratinib and atezolizumab in urothelial cancer 3:23
FORT-2: rogaratinib and atezolizumab in urothelial cancer
Jonathan Rosenberg • 4 Jun 2021
IMpower010: adjuvant atezolizumab improves DFS in resected stage II-IIIA NSCLC 4:50
IMpower010: adjuvant atezolizumab improves DFS in resected stage II-IIIA NSCLC
Heather A. Wakelee • 9 Jun 2021
Lung cancer updates at ASCO 2021 2:00
Lung cancer updates at ASCO 2021
David Spigel • 26 May 2021
Immune checkpoint inhibitors in urothelial bladder cancer 2:01
Immune checkpoint inhibitors in urothelial bladder cancer
Srikala Sridhar • 8 Jun 2021
Next steps in NSCLC: checkpoint inhibitors plus cellular therapy 4:13
Next steps in NSCLC: checkpoint inhibitors plus cellular therapy
Bruna Pellini • 25 May 2021
Highlights from ESMO Breast 2021 1:22
Highlights from ESMO Breast 2021
Marleen Kok • 12 May 2021
Where does immuno-oncology fit in the treatment landscape of TNBC? 4:13
Where does immuno-oncology fit in the treatment landscape of TNBC?
Rebecca Dent • 29 Apr 2021
Triple therapy for melanoma 3:05
Triple therapy for melanoma
Reinhard Dummer • 22 Mar 2021
MiST: personalized approaches to mesothelioma treatment 8:21
MiST: personalized approaches to mesothelioma treatment
Dean Fennell • 19 Apr 2021
IMbrave150: updated data on atezo plus bev versus sorafenib in HCC 3:05
IMbrave150: updated data on atezo plus bev versus sorafenib in HCC
Peter R. Galle • 20 Apr 2021
Triplet therapies for advanced metastatic melanoma 6:58
Triplet therapies for advanced metastatic melanoma
Paolo Ascierto • 19 Apr 2021
PD-1/VEGFR blockade for liver cancer 1:23
PD-1/VEGFR blockade for liver cancer
David Pinato • 16 Apr 2021
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals